Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Eric Davis

Showing results (21-30 of 87) with videos related to

Pageof 9
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 24, 2008
Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screenLloyd T Lam, R Eric Davis, Vu N Ngo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profilingLloyd T Lam, R Eric Davis, Jackie Pierce, et al.
The Journal of Biological Chemistry|December 30, 2010
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomideChad C Bjorklund, Wencai Ma, Zhi-Qiang Wang, et al.
Blood|December 28, 2007
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphomaLloyd T Lam, George Wright, R Eric Davis, et al.
Nature|March 31, 2006
A loss-of-function RNA interference screen for molecular targets in cancerVu N Ngo, R Eric Davis, Laurence Lamy, et al.
Cell Death & Disease|February 11, 2026
Inhibition of autoantigen-induced B-cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)Patryk Górniak, Anna Polak, Anna Rams, et al.
Blood|June 9, 2016
Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemiaSujan Piya, Steven M Kornblau, Vivian R Ruvolo, et al.
Biochimica Et Biophysica Acta|December 26, 2015
Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cellsPeter P Ruvolo, Vivian R Ruvolo, Christopher B Benton, et al.
Blood|December 18, 2010
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expressionChristina M Annunziata, Lidia Hernandez, R Eric Davis, et al.
Molecular Cancer Research : MCR|August 25, 2017
B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic LeukemiaHima V Vangapandu, Ondrej Havranek, Mary L Ayres, et al.
Pageof 9

Showing results (21-30 of 87) with videos related to

Sort By:
Pageof 9
Proceedings of the National Academy of Sciences of the United States of America|December 24, 2008
Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screenLloyd T Lam, R Eric Davis, Vu N Ngo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profilingLloyd T Lam, R Eric Davis, Jackie Pierce, et al.
The Journal of Biological Chemistry|December 30, 2010
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomideChad C Bjorklund, Wencai Ma, Zhi-Qiang Wang, et al.
Blood|December 28, 2007
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphomaLloyd T Lam, George Wright, R Eric Davis, et al.
Nature|March 31, 2006
A loss-of-function RNA interference screen for molecular targets in cancerVu N Ngo, R Eric Davis, Laurence Lamy, et al.
Cell Death & Disease|February 11, 2026
Inhibition of autoantigen-induced B-cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)Patryk Górniak, Anna Polak, Anna Rams, et al.
Blood|June 9, 2016
Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemiaSujan Piya, Steven M Kornblau, Vivian R Ruvolo, et al.
Biochimica Et Biophysica Acta|December 26, 2015
Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cellsPeter P Ruvolo, Vivian R Ruvolo, Christopher B Benton, et al.
Blood|December 18, 2010
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expressionChristina M Annunziata, Lidia Hernandez, R Eric Davis, et al.
Molecular Cancer Research : MCR|August 25, 2017
B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic LeukemiaHima V Vangapandu, Ondrej Havranek, Mary L Ayres, et al.
Pageof 9